Speedoside



Compound IDCDAMM01802
Common nameSpeedoside
IUPAC name[2-(hydroxymethyl)-10-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-5-yl] 3-[3-hydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoate
Molecular formulaC30H38O18

Experimental data

Retention time15.35
Adduct[M+Na]+
Actual mz709.186
Theoretical mz709.195
Error13.42
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.1675

Identifiers and class information

Inchi keyANEVGLDJVAGIAL-XIZYATIWNA-N
SmilesO=C(OC1C2OC2(CO)C3C(OC=CC13)OC4OC(CO)C(O)C(O)C4O)C=CC5=CC=C(OC6OC(CO)C(O)C(O)C6O)C(O)=C5
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)11
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)21
Number of reactive functional groups (#rtvFG)5
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)686.619
Computed dipole moment(dipole)3.628
Total solvent accessible surface area (SASA)945.847
Hydrophobic component of SASA (FOSA)347.947
Hydrophilic component of SASA (FISA)412.022
Pie component of the SASA (PISA)185.879
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1827.28
Number of hydrogen bond donors (donorHB)9
Number of hydrogen bond acceptors (accptHB)26.6
Free energy of solvation of dipole (dip^2/V)0.0072024
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0843688
Globularity descriptor (glob)0.764211
Predicted polarizability in cubic angstroms (QPpolrz)55.265
Predicted hexadecane/gas partition coefficient (QPlogPC16)21.616
Predicted octanol/gas partition coefficient (QPlogPoct)46.772
Predicted water/gas partition coefficient (QPlogPw)40.812
Predicted octanol/water partition coefficient (QPlogPo/w)-3.328
Predicted aqueous solubility (QPlogS)-1.614
Conformation-independent predicted aqueous solubility (CIQPlogS)-2.776
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.234
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1.227
Predicted brain/blood partition coefficient (QPlogBB)-5.406
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.353
Predicted skin permeability, log Kp (QPlogKp)-6.442
PM3 calculated ionization potential (IP(ev))9.043
PM3 calculated electron affinity (EA(eV))0.804
Number of likely metabolic reactions (#metab)11
Prediction of binding to human serum albumin (QPlogKhsa)-2.088
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)292.386
Number of nitrogen and oxygen atoms (#NandO)18
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P52789HK2Hexokinase type IIT96685SEA
P60568IL2Interleukin-2T61698SEA
P14679TYRTyrosinaseT97035SEA
P20916MAGMyelin-associated glycoprotein (by homology)T95286SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
O43826SLC37A4Glucose-6-phosphate translocaseT47306SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T96685DI0133Epidermal dysplasias[ICD-11: EK90]P52789HK2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T95286DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P20916MAG
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025